Royalty Pharma PLC logo

Royalty Pharma PLC

$ 40.19 +0.01 (+0.02%) 10:08 PM EST
P/E:
37.91
P/B:
2.93
Market Cap:
$ 17.64B
Enterprise V:
$ 21.34B
Volume:
1.73M
Avg Vol (2M):
1.79M
Also Trade In:
Volume:
1.73M
Market Cap $:
17.64B
PE Ratio:
37.91
Avg Vol (2-Month):
1.79M
Enterprise Value $:
21.34B
PB Ratio:
2.93
GF Score:
Year:
Embed
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
Royalty Pharma PLC is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The company assembles a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's therapies, which includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Johnson & Johnson's Tremfya, Gilead's Trodelvy, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates.
Name Current Vs Industry Vs History
Cash-To-Debt 0.48
Equity-to-Asset 0.34
Debt-to-Equity 1.18
Debt-to-EBITDA 6.47
Interest Coverage 5.69
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 2.19
Distress
Grey
Safe
Beneish M-Score -3.13
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 37.56
9-Day RSI 36.71
14-Day RSI 37.55
6-1 Month Momentum % 6.89
12-1 Month Momentum % 16.12

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 19.22
Quick Ratio 19.22
Cash Ratio 18.66

Financials (Next Earnings Date:2022-11-10 Est.)

RPRX's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:RPRX

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Embed

Valuation Box

Year:
Embed

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 2,259.477
EPS (TTM) ($) 1.06
Beta 0
Volatility % 15.32
14-Day RSI 37.55
14-Day ATR ($) 0.865302
20-Day SMA ($) 41.5435
12-1 Month Momentum % 16.12
52-Week Range ($) 34.86 - 44.75
Shares Outstanding (Mil) 438.84

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Royalty Pharma PLC Filings

Document Form Filing Date
No Filing Data

Royalty Pharma PLC Analysis

Share your research

Headlines

See More
No news.